Sutro Biopharma因业绩未达预期而股价暴跌

路透中文
Aug 12
BUZZ-<a href="https://laohu8.com/S/STRO">Sutro Biopharma</a>因业绩未达预期而股价暴跌

8月12日 - ** 周三上午,肿瘤药物开发商Sutro Biopharma(STRO.O)股价下跌约25%,跌至五个月以来的最低点

** 据LSEG报导,该公司第二季度营收 (link) 为980万美元,低于1310万美元的预期

** 本季度亏损为3850万美元,而分析师预期为3380万美元

** Sutro预计将于2026年第三季度启动STRO-006的I期临床试验

** 公司预计现有现金储备足以支撑运营至至少2028年第二季度

** 据LSEG报导,主要股东包括激进投资基金BVF Partners、Perceptive Advisors和OrbiMed Advisors

** 目前14位分析师对该股的平均评级为“买入”,目标价中位数为50美元

** 周三上午盘中,股价下跌6.08美元至18.96美元;自5月以来股价已下跌一半,但年初至今仍上涨逾60%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10